ArticleJournal of Korean medical science2025
10-Year Change and Projection in Prevalence and Incidence of Exudative Age-Related Macular Degeneration in Korea.
Article in Journal of Korean medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Food-Grade Microgels for Age-Related Macular Degeneration: Design, Fabrication, and Targeted Delivery.Gels (Basel, Switzerland) · 2026Review
- Trends in Widefield Fundus Photography and Optical Coherence Tomography Examination in South Korea (2015-2024).Korean journal of ophthalmology : KJO · 2026Observational
- Prevalence, incidence and risk factors of visual disability in patients with exudative age-related macular degeneration: a nationwide population-based study in Korea.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundUpdating the recent epidemiology of exudative age-related macular degeneration (AMD) is crucial for understanding the epidemiological trend of the disease, preparing healthcare strategies, and providing data for global comparisons. This study aimed to estimate the nationwide trend in prevalence and incidence of exudative AMD in Korea.
methodsIn this nationwide population-based study using the National Health Insurance Service data, patients who have registration code for exudative AMD and aged 40 years or older were extracted from 2013 to 2022. Cumulative prevalence from 2013 onwards, annual prevalence, and incidence was estimated per 10,000 people. We also calculated age-standardized estimates using the World Health Organization population proportions. Linear regression to test time trend was performed. The annual prevalence and incidence were predicted using time series analysis.
resultsThe crude cumulative prevalence of exudative AMD was 42.7 in 2022, with men having a higher prevalence than women (51.3 vs. 34.6). The annual prevalence rose from 10.7 in 2013 to 22.5 in 2022 (age-standardized,
conclusionThe prevalence and incidence of exudative AMD in Korea has been increased annually, especially in the elderly group. With the Korean and global population aging, there will be a growing burden from visual impairment and medical expenses associated with exudative AMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.